Sources audit

Master list of primary sources for every article on Peppu Wiki. Each article's quantitative claims (binding affinities, dosing ranges, half-life figures, gene-expression numbers, regulatory placements) trace back to one of the citations below. PubMed IDs (PMID) and DOIs link to the source so claims can be checked independently.

Last audit: 2026-05-17. If you find a claim in an article that does not match its cited source, email [email protected] with the article, the claim text, and the relevant source.

BPC-157

TB-500 (Thymosin β-4)

GHK-Cu

Tirzepatide

Semaglutide

MOTS-c

Ipamorelin

Reconstitution (lyophilized peptide handling)

Methodology. Sources prioritized in this order: (1) FDA, EMA, WADA, USP official documents for regulatory and pharmacopoeial claims · (2) peer-reviewed primary literature indexed in PubMed for mechanistic and clinical claims · (3) major review articles for synthesis claims. Vendor marketing copy, self-published blogs, and unmoderated forum posts are NOT accepted as citations for efficacy claims (they may be cited only when documenting that a community practice exists, never to support that it works).

Research framing only. Peppu Wiki documents the published research literature surrounding peptide compounds. Articles describe in-vitro and animal-model evidence, regulatory status, and community-reported protocols. Nothing on this site is medical advice, a recommendation for human use, or a substitute for consultation with a qualified clinician. All compounds discussed are research-use only. Citations should be verified at the source before relying on any quantitative claim.

View edit history of this page